Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...

The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

At the same time, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has progressed, and the UK has ...

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.

Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide, cutting the monthly price to $349, earlier than expected, for people willing to ...

The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...